At first prescription, the prescriber/healthcare professional (HCP) should discuss with the patient the risks described within the discussion guide. The guide is aimed at increasing awareness about the potential risk of haematological effects and liver effects, risk of hypertension, serious infections and teratogenicity with teriflunomide and providing guidance on how to manage that risk. For hard copies of this information, please contact axunio Pharma via email to [email protected].